My Stocks and Shares ISA has two roles. The first is to build up my wealth while I’m working. The second is to release income after I retire.
I’ve got some whizzy growth stocks in there, including cosmetics maker Warpaint and outsourcing firm Costain Group. But I’ve also got a heap of income-paying FTSE 100 blue-chips, and I’m pinning most of my hopes on them.
Today, they’re largely overlooked by investors, who would rather ride with the Magnificent Seven US tech heroes. My FTSE faves may be a little boring but they’re beautiful in their own way.
FTSE 100 beauties
I prefer to buy stocks when they’re out of favour, rather than riding high. That allows me to pick them up at a discounted price, and secure an elevated yield.
My view is that UK dividend stocks would swing back into favour once interest rates peak and savings rates and bond yields fell. That scenario has taken longer to pan out than I hoped, but it should happen at some point. And when it does, I hope to bag some share price growth on top of my dividend income.
My favourite less-than-magnificent seven blue-chips are GSK (LSE: GSK), Lloyds Banking Group, Legal & General Group, M&G, Phoenix Group Holdings, Unilever and Taylor Wimpey.
They’re dull compared to, say, Nvidia and Tesla, but do offer the occasional flash of excitement.
The Taylor Wimpey share price is up 33.79% over the last year. And it still has a trailing yield of 6.1%. Lloyds is up 29.11% and yields 4.64% (that’s forecast to hit 5.5%).
The Phoenix share price has been boring for yonks but it does yield 9.92%. It was a beautiful day when the last dividend hit my portfolio.
Dividend income heroes
GSK‘s been interesting, but in the wrong way. I bought its shares in March and again in June, thinking it was due a share price recovery. So far, I’m down 10.73%. These are early days but I expected better. Over one year, they’re up 8.61%.
Pharmaceutical stocks are thought to be defensive but can also be volatile. Bringing new treatments to market is a tortuous process, with potential failure at every turn. Even the blockbuster successes will come off patent at some point, hitting sales, so exciting new treatments need to be found.
Plus there’s the threat of litigation. GSK’s heartburn treatment Zantac has been accused of causing cancer. News that cases would go to trial in the US knocked 10% off the GSK share price in a single day. It has yet to recover and probably won’t until the trial is done. And maybe not even then if the verdict goes the wrong way.
I’ll stick it out though. Over the longer run, I think GSK shares will come good, and today’s so-so 3.89% yield will finally recover.
These seven oh-so-boring stocks will sit in my Stocks and Shares ISA for years doing their thing. When I retire, I expect them to deliver a stream of tax-free income, and maybe some capital growth too. Beautiful.
The post These boring but beautiful picks will always have a place in my Stocks and Shares ISA appeared first on The Motley Fool UK.
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy — and discover:
Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
How to potentially get paid by the weather
Electric Vehicles’ secret backdoor opportunity
One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
As GSK’s share price drops 15%, should I buy, sell, or hold?
I’m considering 3 top UK dividend stocks for my portfolio this July
These 3 big-name FTSE 100 shares are stinking out my portfolio. Time to sell?
Down 17%, does the GSK share price scream buy?
Here’s how I’d start investing in the stock market with a spare £800
Harvey Jones has positions in GSK, Legal & General Group Plc, M&g Plc, Phoenix Group Plc, and Taylor Wimpey Plc. The Motley Fool UK has recommended GSK and M&g Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
